Loading...
NPI 1447843750 · Pinecrest, FL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Pro Diametrics Corp is a clinical medical laboratory provider located in Pinecrest, Florida. This profile covers 87 Medicare and 98 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Pro Diametrics Corp |
| Address | 9627 S Dixie Hwy |
| City | Pinecrest |
| State | FL |
| ZIP | 33156 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | February 17, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $12.8M |
| Medicaid | $792.4K |
PRO DIAMETRICS CORP is a clinical molecular diagnostics laboratory focused heavily on genetic sequencing and targeted molecular tests, as reflected by its top Medicare codes including 81307, 81321, 81249, 81223 and multiple panel codes such as 81419 and 81443. The presence of high-revenue panel codes (81419, 81443, 81412, 81441) alongside many single-gene and targeted oncology codes suggests the operation combines broad multi-gene panels with high-volume single-gene technical testing workflows. This mix indicates a service-line emphasis on genetic disease and oncology-related testing rather than general anatomic pathology or routine chemistry panels.
Medicare revenue ($12.8M) dwarfs Medicaid revenue ($792.4K) for this provider, indicating Medicare is the dominant payer by scale. The provider’s top three Medicare codes account for 25.6% of Medicare revenue, signaling moderate revenue concentration in a small set of high-value tests while the remainder of Medicare revenue is distributed across many additional molecular codes. By contrast, the top three Medicaid codes account for 25.5% of Medicaid revenue, showing a similar concentration pattern within the smaller Medicaid book of business.
Several individual Medicare codes show the provider at or above typical national volumes: examples include 81210 (rank #2 of 30, 97th percentile) and 81233 (rank #1 of 10, 100th percentile), which the data label as notably above typical national volume or at the top of national peers. These rankings indicate PRO DIAMETRICS has unusually high national share for specific targeted molecular tests, consistent with a specialized testing footprint that captures outsized volumes for certain assays. However, many other Medicare code ranks are described as "typical, unremarkable volume," so the provider appears to be selective in which assays it leads.
In-state Medicaid comparisons show a strong dominant position across many hereditary and oncology-related codes. Multiple Medicaid codes are ranked #1 in-state and described as "100th percentile" or "extreme outlier," including 81321, 81298, 81249, 81223, 81311 and others. That pattern signals PRO DIAMETRICS is a major Medicaid provider in Florida for a broad set of genetic sequencing tests, often reporting far above typical state volumes for these assays. For payers and network managers, this suggests the lab is a key in-state supplier for specialized molecular testing.
Revenue concentration by payer: for Medicare the precomputed top-3 codes represent 25.6% of Medicare revenue, indicating a modest concentration that still leaves three-quarters of Medicare revenue tied to many other codes. For Medicaid the top-3 codes represent 25.5% of Medicaid revenue, a near-identical concentration profile at a much smaller absolute dollar scale. Both payer books therefore combine a few high-revenue assays with a long tail of lower-revenue tests, which has implications for contract negotiations that might focus on those top panel and sequencing codes.
Several high-cost panel codes on Medicare have relatively small claim counts but large average payments (for example, 81419 and 81443 at $2400 avg paid/claim), producing sizable line-item revenue despite lower claim volumes. That pattern—fewer claims with high per-claim reimbursement—contrasts with the high-claim, lower-unit-pay codes (e.g., many single-gene assays) and indicates the lab captures both high-margin panel work and high-throughput single-gene testing. Payers should note reimbursement exposure to a handful of expensive panels when modeling utilization and spend.
The provider was enumerated on 2021-02-17 (~5 years ago), giving it a relatively recent NPI tenure compared with many legacy labs. Despite a recent enumeration date, the national and state rank data show the lab has rapidly established significant volumes on selected assays, suggesting aggressive market entry or consolidation of specialist testing referrals. Analysts evaluating competition should weigh the short public tenure against the provider’s fast attainment of leading rank positions for many state-level Medicaid codes.
Competitive implications differ by payer: nationally for Medicare the provider is a strong niche player—top-percentile ranks on several codes but many codes still labeled "typical, unremarkable"—so it is not a broad national dominator but rather a leader on select assays. In Florida Medicaid the provider behaves like a dominant statewide supplier across many genetic tests (numerous #1 in-state rankings and "extreme outlier" or "notably above typical" labels), meaning local payers are likely to rely on or encounter this lab frequently in-network and in utilization reviews.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
87 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81307 | The lab analyst performs the technical lab test on a specimen such as blood, to analyze the entire gene sequence for the partner and localizer of BRCA2 (PALB2) gene. | 1,400 | $660 | $925.5K |
| 81321 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the phosphatase and tensin homolog, or PTEN, gene. | 1,550 | $590 | $910.8K |
| 81249 | The lab analyst performs the technical lab test to analyze known the full gene sequence of the glucose–6–phosphate dehydrogenase (G6PD) gene. | 1,430 | $590 | $839.4K |
| 81223 | The lab analyst performs the technical lab test to analyze the entire gene sequence for cystic fibrosis transmembrane conductance regulator gene, also known as CFTR. | 1,580 | $490 | $769.1K |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 1,260 | $590 | $739.7K |
| 81419 | The lab analyst performs the technical lab test on a specimen such as blood to conduct a genomic sequence analysis panel. The test evaluates the genetic sequences of at least the 24 genes listed in… | 270 | $2,400 | $657.6K |
| 81443 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least 15 genes, such as the 20 gene examples listed in the code descriptor. The… | 250 | $2,400 | $597.6K |
| 87483 | The lab analyst performs the technical steps to detect multiple types or subtypes of possible central nervous system pathogens listed in the code. The analyst uses multiplex amplified probe technique… | 1,140 | $410 | $463.9K |
| 81320 | The lab analyst performs the technical lab test to detect the presence of common changes in the phospholipase C gamma 2 gene (PLCG2). | 1,580 | $290 | $451.9K |
| 81334 | The lab analyst performs the technical lab test to detect the presence of specific changes in the runt related transcription factor 1 (RUNX) gene for targeted sequence analysis, such as exons 3–8. | 1,280 | $320 | $412.5K |
Showing 1–10 of 87
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 87 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
87 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81307 | 6 | 30 | 320 | $660 | $508.3K |
| 81443 | 2 | 10 | 170 | $2,400 | $481.7K |
| 81321 | 5 | 30 | 430 | $580 | $467.7K |
| 87483 | 1 | 10 | 1,140 | $410 | $464.4K |
| 81238 | 6 | 20 | 330 | $590 | $440.3K |
| 81419 | 4 | 10 | 90 | $2,400 | $434.1K |
| 81412 | 1 | 10 | 170 | $2,400 | $410.3K |
| 81249 | 4 | 20 | 290 | $590 | $383.1K |
| 81223 | 3 | 20 | 340 | $490 | $329.3K |
| 81351 | 9 | 20 | 210 | $630 | $307.8K |
Showing 1–10 of 87
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
98 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81321 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the phosphatase and tensin homolog, or PTEN, gene. | 1,860 | $40 | $78.2K |
| 81317 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the postmeiotic segregation increased 2 [S. cerevisiae], or PMS2 gene. | 730 | $70 | $51.7K |
| 81298 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 6 [E. coli], or MSH6 gene. | 730 | $70 | $47.5K |
| 81249 | The lab analyst performs the technical lab test to analyze known the full gene sequence of the glucose–6–phosphate dehydrogenase (G6PD) gene. | 840 | $60 | $46.9K |
| 81223 | The lab analyst performs the technical lab test to analyze the entire gene sequence for cystic fibrosis transmembrane conductance regulator gene, also known as CFTR. | 750 | $60 | $44K |
| 81311 | The lab analyst performs the technical lab test to analyze variants in exon 2, such as codons 12 and 13, and exon 3, such as codon 61, for the neuroblastoma RAS viral, v–ras, oncogene homolog, also… | 1,090 | $40 | $42.4K |
| 81302 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the methyl CpG binding protein 2, or MECP2 gene. | 100 | $420 | $42.2K |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 920 | $40 | $36.8K |
| 81292 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutL homolog 1, or MLH1 gene, also known as the colon cancer or nonpolyposis type 2 gene. | 170 | $170 | $29.2K |
| 81410 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least nine genes that the code descriptor lists that may relate to aortic… | 70 | $400 | $27K |
Showing 1–10 of 98
How this provider's Medicaid billing volume and revenue compare to other Florida providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Florida median
98 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 11 | 10 | 80 | $50 | $2.4M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 64 | 70 | 500 | $30 | $231.8K |
| 81443 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least 15 genes, such as the 20 gene examples listed in the code descriptor. The… | 5 | 10 | 200 | $440 | $201.7K |
| 81329 | The lab analyst performs the technical lab test to detect deletions in the survival of motor neuron 1 (SMN1), telomeric, gene and may also analyze the survival of motor neuron 2 (SMN2), centromeric,… | 5 | 10 | 200 | $20 | $72K |
| 81162 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the BRCA1, DNA repair–associated gene, also called BRCA1; and BRCA2, DNA repair–associated gene, also called… | 8 | 10 | 120 | $370 | $67K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 26 | 110 | 490 | $40 | $64.4K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 33 | 190 | 640 | $10 | $59.9K |
| 81243 | The lab analyst performs the technical lab test to detect the presence of changes in the gene for fragile X messenger ribonucleoprotein 1, also known as FMR1, typically to detect common abnormal… | 5 | 10 | 80 | $10 | $42.6K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 41 | 190 | 420 | $20 | $40.4K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 36 | 40 | 230 | $60 | $38.5K |
Showing 1–10 of 98
Other providers in the same ZIP code as Pro Diametrics Corp, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Life Cares Solutions, LLC. | FL | Attendant Care Provider | $0 | $11.1M |
| Luna Home Care Services Inc. | FL | In Home Supportive Care Agency | $0 | $9.2M |
| American Access Care Of Miami Asc LLC | FL | Ambulatory Surgical Clinic/Center | $1.4M | $532.6K |
| John Torregrosa | FL | Podiatrist | $836.5K | $0 |
| Joshua Fox | FL | MOHS-Micrographic Surgery Physician | $570K | $0 |
| Richard Prager | FL | Pulmonary Disease Physician | $353.4K | $0 |
| Jeremy Tabak | FL | Pulmonary Disease Physician | $320.7K | $0 |
| Deborah Longwill | FL | Dermatology Physician | $265.7K | $2.9K |
| Abelardo Corona | FL | Internal Medicine Physician | $240.6K | $0 |
| Philip Claire | FL | Vascular & Interventional Radiology Physician | $205K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.